HotSpot Therapeutics Secures $65M Back to HomeBOSTON, MA, HotSpot Therapeutics has announced the completion of a $65 million Series B financing.
HotSpot Therapeutics, a biotechnology company pioneering the discovery and development of first-in-class allosteric therapies targeting nature's regulatory sites, today announced the completion of a $65 million Series B financing.
"We are thrilled to have the support of a top tier investor syndicate to realize our vision of designing and developing first-in-class allosteric medicines," said Jonathan Montagu, CEO and co-founder of HotSpot Therapeutics.
HotSpot Therapeutics is creating a new paradigm for allosteric medicines that exploits natural control mechanisms.
About HotSpot TherapeuticsHotSpot Therapeutics is targeting nature's regulatory mechanisms to create allosteric medicines that exhibit high precision and potency.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
Founders of a previously successful business have a 30% chance of success with their next venture.
Search Startup Around
Boost Your Discovery with Us
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.